Evaluation of prognostic factors for secondary cytoreductive surgery in Chinese patients with recurrent epithelial ovarian carcinoma.

OBJECTIVE Secondary cytoreductive surgery (SCS) is reported to be beneficial for patients with recurrent epithelial ovarian carcinoma (EOC). The current study is to evaluate risk factors that would affect the surgical optimal resection rate and prognosis of recurrent EOC after SCS in Chinese patients. METHODS In our study, 44 patients with recurrent EOC treated with SCS at Shandong Cancer Hospital were retrospectively reviewed. Patient characteristics were collected and multivariate logistic regression was used to analyze factors that affect the optimal surgical resection rate. The overall survival rate was calculated by the Kaplan-Meier method. Cox proportional-hazards regression was used to analyze risk factors that affect the overall survival of these patients. RESULTS 90.9% (40/44) patients achieved optimal cytoreductive surgery. Logistic regression did not find any factor that affects the optimal surgical resection rate. Among 24 cases that received chemotherapy before SCS, 18 cases achieved good response and thus had a better survival rate after SCS. Multivariate Cox proportional hazard regression analysis indicated that differentiation, the extent of surgical resection during the initial surgery, and course and efficacy of chemotherapy prior to SCS, and efficacy of chemotherapy after the first recurrence significantly correlated with survival of patients with recurrent cancer (P < 0.05; OR < 1). CONCLUSION Selection of patients that are suitable to perform SCS will enhance the optimal surgical resection rate. The prognosis of Chinese patients with recurrent EOC after SCS is affected by histologic grade, the extent of residual disease and the effect of chemotherapy after first relapse.

[1]  G. Scambia,et al.  Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. , 2014, Gynecologic oncology.

[2]  M. Moreno-Eutimio,et al.  Management of recurrent epithelial ovarian cancer. , 2014, Gland surgery.

[3]  M. Del Pilar Estevez Diz,et al.  Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. , 2014, Gynecologic oncology.

[4]  G. Scambia,et al.  Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series. , 2014, Gynecologic oncology.

[5]  Xiaoxiang Chen,et al.  Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer , 2013, Journal of experimental & clinical cancer research : CR.

[6]  J. Ledermann,et al.  Optimal first-line treatment in ovarian cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Berek,et al.  Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort , 2011, British Journal of Cancer.

[8]  J. Sehouli,et al.  Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. , 2009, Anticancer research.

[9]  R. Sayer,et al.  Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. , 2007, Gynecologic oncology.

[10]  R. Bristow,et al.  Secondary cytoreductive surgery for localized recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome , 2006 .

[11]  E. Venkatraman,et al.  Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma , 2006, Cancer.

[12]  R. Bristow,et al.  Secondary cytoreduction for patients with recurrent ovarian cancer , 2005, Current oncology reports.

[13]  Y. Taketani,et al.  Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection , 2005, British Journal of Cancer.

[14]  I. Christensen,et al.  Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  N. Teng,et al.  Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits? , 2004, Cancer.

[16]  R. Zang,et al.  Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: A retrospective case-control study , 2003, International Journal of Gynecologic Cancer.

[17]  A. Carbone,et al.  Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. , 2001, Gynecologic oncology.

[18]  J. Wolf,et al.  Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. , 2001, Gynecologic oncology.

[19]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[20]  G. Gardner,et al.  Current and future directions of clinical trials for ovarian cancer. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[21]  D. Chi,et al.  Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. , 2009, Gynecologic oncology.

[22]  N. Spirtos,et al.  The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma , 2000, Cancer.